Nominee Photo (add first and last name as file name)*

Nominee Name*

Rui (Sammi) Tang

Present Position*

SVP, Global Head of Quantitative Sciences and Evidence Generation, Astellas

Former Position*

VP, Global Head of Biometrics, Servier

Degree*

Ph.D, MBA

Fields of Major Statistical Activities*

Adaptive design, RWE analytics, decision making analytics, survival analysis, AI/ML

Selected publication*

1. Baron, E., Lin, M., Zhu, J. **Tang,R.** (2024). Enhancing Randomized Controlled Trials: A Bayesian Divide-and-Conquer Approach for Borrowing External Control Data. *Stat Biosci* https://doi.org/10.1007/s12561-024-09465-2

2. Rongji Mu, Xiaojiang Zhan, **Tang,R.**, Ying Yuan, A Bayesian latent-subgroup platform design for dose optimization, Biometrics*, Volume 80, Issue 3, September 2024* ujae093, https://doi.org/10.1093/biomtc/ujae093
3. Zhao, Y., **Tang, R.,** Du, Y., & Yuan, Y. (2023). A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. *Biometrics, 79(2), 1459-1471. Oxford University Press. doi: 10.1111/biom.13694*
4. Hampson, L. V., Degtyarev, E., **Tang, R.,** Lin, J., Rufibach, K., & Zheng, C. (2023). Comment on "Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment". *Statistics in Biopharmaceutical Research, 15(1), 23-26. Taylor & Francis. doi: 10.1080/19466315.2021.1994459*
5. Ghadessi, M., Di, J., Wang, C., Toyoizumi, K., Shao, N., Mei, C., Demanuele, C., **Tang, R**., McMillan, G., & Beckman, R. A. (2023). Decentralized clinical trials and rare diseases: a Drug Information Association Innovative Design Scientific Working Group (DIA-IDSWG) perspective. *Orphanet Journal of Rare Diseases, 18(1), 79. BioMed Central London. doi.org/10.1186/s13023-023-02693-7*
6. Bhagnani, T., Zhu, J. J., Freyer, D. R. R., O'Dwyer, K. M., Roth, M. E., Wolfson, J. A., Meng, Q., **Tang, R.** S., & Paglia, R. G. (2022). Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data. *Blood, 140(Supplement 1), 2190-2192. American Society of Hematology. doi.org/10.1182/blood-2022-162681*
7. Beckman, R. A., Natanegara, F., Singh, P., Cooner, F., Antonijevic, Z., Liu, Y., Mayer, C., Price, K., **Tang, R.,** & Xia, A., et al. (2022). Advancing innovative clinical trials to efficiently deliver medicines to patients. *Nature Reviews Drug Discovery, 21(8), 543-544. Nature Publishing Group UK London. doi.org/10.1038/d41573-022-00109-y*
8. Zhu, J., & ***Tang, R.*** (2022). A proper statistical inference framework to compare clinical trial and real-world progression-free survival data. Statistics in Medicine, 41(29), 5738-5752. doi.org/10.1002/sim.9590
9. Mu, R., Xu, J., **Tang, R.,** Kopetz, S., & Yuan, Y. (2022). A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. *Statistics in Medicine, 41(2), 374-389. Wiley Online Library. doi.org/10.1002/sim.9242*
10. McMillan, G., Mayer, C., **Tang, R.,** Liu, Y., LaVange, L., Antonijevic, Z., & Beckman, R. A. (2022). Planning for the next pandemic: ethics and innovation today for improved clinical trials tomorrow. *Statistics in Biopharmaceutical Research, 14(1), 22-27. Taylor & Francis. doi: 10.1080/19466315.2021.1918236*
11. **Tang, R.**, Zhu, J., Chen, T.-T., Liu, F., Jiang, X., Huang, B., Lee, J. J., & Beckman, R. A. (2022). Impact of COVID-19 pandemic on oncology clinical trial design, data collection, and analysis. *Contemporary Clinical Trials, 116, 106736. Elsevier. DOI: 10.1016/j.cct.2022.106736*
12. Baron, E., Zhu, J., **Tang, R.,** & Chen, M.-H. (2022). Bayesian divide-and-conquer propensity score based approaches for leveraging real-world data in single-arm clinical trials. *Journal of*

Biopharmaceutical Statistics, 32(1), 75-89. Taylor & Francis.
DOI: 10.1080/10543406.2021.2011904

13. Manitz, J., Kan-Dobrosky, N., Buchner, H., Casadebaig, M.-L., Degtyarev, E., Dey, J., Haddad, V., Jie, F., Martin, E., Mo, M., Rufibach, K., Shentu, Y., Stalbovskaya, V., **Tang, R.** & others. (2022). Estimands for overall survival in clinical trials with treatment switching in oncology. *Pharmaceutical Statistics, 21(1), 150-162. Wiley Online Library. DOI: 10.1002/pst.2158*
14. Antonijevic, Z., Liu, Y., **Tang, R.,** Huml, J. R., Beckman, R. A., Mayer, C., McMillan, G. (2021). Patient benefits from innovative designs in rare diseases. *In Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives (pp. 147-160). Springer International Publishing. doi.org/10.1007/978-3-030-78605-2_26*
15. **Tang, R.,** Beckman, R. A., Liu, Y., Xu, H., Ghadessi, M., Chen, C., Antonijevic, Z. (2021). Novel Approaches to Clinical Trials in Rare Diseases. In Rare Disease Drug Development: Clinical, Scientific, Patient, and Caregiver Perspectives (pp. 127-145). Springer International Publishing. doi.org/10.1007/978-3-030-78605-2_9
16. Degtyarev, E., Rufibach, K., Shentu, Y., Yung, G., Casey, M., Englert, S., Liu, F., Liu, Y., Sailer, O., Siegel, J., Sun S, **Tang, R.** & others. (2020). Assessing the impact of COVID-19 on the clinical trial objective and analysis of oncology clinical trials—application of the estimand framework. *Statistics in Biopharmaceutical Research, 12(4), 427-437. Taylor & Francis. doi: 10.1080/19466315.2020.1785543.*
17. Ghadessi, M., **Tang, R.,** Zhou, J., Liu, R., Wang, C., Toyoizumi, K., Mei, C., Zhang, L., Deng, C. Q., & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials—by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). *Orphanet Journal of Rare Diseases, 15(1), 1-19. BioMed Central.* doi.org/10.1186/s13023-020-1332-x
18. Lu, R., **Tang, R.,** & Huang, J. (2019). Clinical application of molecular features in therapeutic selection and drug development. *In Statistical Methods in Biomarker and Early Clinical Development (pp. 137-166). Springer International Publishing.* doi.org/10.1007/978-3-030-31503-0_8
19. **Tang, R**., Shen, J., & Yuan, Y. (2019). ComPAS: a Bayesian drug combination platform trial design with adaptive shrinkage. *Statistics in Medicine, 38(7), 1120-1134.* doi: 10.1002/sim.8026.
20. Li, M., & **Tang, R**. (2019). Statistical Considerations in the Development of Companion Diagnostic Device. *In Statistical Methods in Biomarker and Early Clinical Development (pp. 67-86). Springer International Publishing.* doi.org/10.1007/978-3-030-31503-0_5
21. Hong, D. S., LoRusso, P., Hamid, O., Janku, F., Kittaneh, M., Catenacci, D. V. T., Chan, E., Bekaii-Saab, T., Gadgeel, S. M., Loberg, R. D., & others. (2019). Phase I study of AMG 337, a highly selective small-molecule MET inhibitor, in patients with advanced solid tumors. Clinical Cancer Research, 25(8), 2403-2413. American Association for Cancer Research. doi: 10.1158/1078-0432.CCR-18-1341.

22. **Tang, R.,** Ma, X., Yang, H., & Wolf, M. (2018). Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial with Time-to-Event Data: Comparing Group Sequential and Various Adaptive Enrichment Designs. *Statistics in Biosciences, 10, 371-404. Springer US.* doi.org/10.1007/s12561-017-9198-8
23. Huang, H., Tang, H., Huang, J., Chen, B., Liu, R., **Tang, R**., Lu, Y., & Yang, P. (2017). Selected Papers of the Inaugural DahShu Data Science Symposium: Computational Precision Health (CPH 2017). *Journal of Computational Biology: A Journal of Computational Molecular Cell Biology, 24(7), 635-636.* doi: 10.1089/cmb.2017.29007.hh.
24. Taylor, J. L., Jain, M., Barto, T. L., Haddad, T., Atkinson, J., Tian, S., **Tang, R**., Marigowda, G., Waltz, D., & Pilewski, J. (2017). 55 Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-week open-label study. *Journal of Cystic Fibrosis, 1(16), S78.* doi: 10.1016/j.jcf.2017.09.012.
25. Glisson, B., Besse, B., Dols, M. C., Dubey, S., Schupp, M., Jain, R., Jiang, Y., Menon, H., Nackaerts, K., Orlov, S., Paz-Ares, L., Ramlau, R., **Tang, R.,** Zhang, Y., Zhu, M. (2017). A randomized, placebo-controlled, phase 1b/2 study of rilotumumab or ganitumab in combination with platinum-based chemotherapy as first-line treatment for extensive-stage small-cell lung cancer. *Clinical Lung Cancer, 18(6), 615-625. Elsevier.* doi: 10.1016/j.cllc.2017.05.007.
26. Taylor-Cousar, J., Jain, M., Barto, T. L., Haddad, T., Atkinson, J., Tian, S., **Tang, R.,** Marigowda, G., Waltz, D., & Pilewski, J. (2017). 55 Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-week open-label study. Journal of Cystic Fibrosis, 1(16), S78. doi: 10.1016/j.jcf.2017.09.012.
27. Zhu, M., **Tang, R.,** Doshi, S., Oliner, K. S., Dubey, S., Jiang, Y., Donehower, R. C., Iveson, T., Loh, E. Y., & Zhang, Y. (2015). Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. *British Journal of Cancer, 112(3), 429-437. Nature Publishing Group.* doi: 10.1038/bjc.2014.649.
28. Kwak, E. L., LoRusso, P., Hamid, O., Janku, F., Kittaneh, M., Catenacci, D. V. T., Chan, E., Bekaii-Saab, T. S., Amore, B., Hwang, Y. C., **Tang, R**. & others. (2015). Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer. *Journal of Clinical Oncology 2015 33:3_suppl, 1-1*. doi.org/10.1200/jco.2015.33.3_suppl.1
29. Catenacci, D. V. T., **Tang, R**., Oliner, K. S., Ang, A., Loberg, R. D., O'Day, E., Xu, P., Henderson, L., Ruzzo, A., Graziano, F., & others. (2015). MET as a prognostic biomarker of survival in a large cohort of patients with gastroesophageal cancer (GEC). *Journal of Clinical Oncology 33:15_suppl, 4034-4034.* DOI:10.1200/jco.2015.33.15_suppl.4034
30. Yang, H., **Tang, R.,** Hale, M., & Huang, J. (2016). A visualization method measuring the performance of biomarkers for guiding treatment decisions*. Pharmaceutical Statistics, 15(2), 152-164.* doi: 10.1002/pst.1728.
31. Iveson, T., Donehower, R. C., Davidenko, I., Tjulandin, S., Deptala, A., Harrison, M., Nirni, S., Lakshmaiah, K., Thomas, A., Jiang, Y., Zhu, M., **Tang, R.,** & others. (2014). Rilotumumab in

combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. *The Lancet Oncology, 15(9), 1007-1018. Elsevier.* doi: 10.1016/S1470-2045(14)70023-3.

32. Van Cutsem, E., Eng, C., Nowara, E., Świeboda-Sadlej, A., Tebbutt, N. C., Mitchell, E., Davidenko, I., Stephenson, J., Elez, E., Prenen, H., Deng, H., **Tang, R.,** & others. (2014). Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. *Clinical Cancer Research, 20(16), 4240-4250.* doi: 10.1158/1078-0432.CCR-13-2752.
33. Zhang, Y., Zheng, J., **Tang, R**., Loh, E., Dubey, S., & Zhu, M. (2014). Pharmacokinetics (PK) and exposure-response (ER) of rilotumumab (Rmab) in patients (pts) with small-cell lung cancer (SCLC). *Journal of Clinical Oncology 32:15_suppl, 7593-7593.* DOI:10.1200/jco.2014.32.15_suppl.7593
34. Ang, A. L., Yang, H., Anderson, A. A., **Tang, R.,** Damore, M. A., & Loberg, R. D. (2014). Prevalence of MET amplification, MET expression, and MET-related genomic alterations in non-small cell lung cancer (NSCLC). *European Journal of Cancer, 50, 161-162.*
35. Doi, T., **Tang, R.,** Zhang, Y., Loh, E., Lizambri, R., & Yasui, H. (2014). Safety, tolerability, and pharmacokinetics (PK) of rilotumumab in Japanese patients (pts) with advanced solid tumors. *Journal of Clinical Oncology 32:3_suppl, 130-130.* DOI:10.1200/jco.2014.32.3_suppl.130.
36. Doi, T., Yamaguchi, K., Komatsu, Y., Muro, K., Nishina, T., Nakajima, T. E., Lizambri, R., Loh, E., **Tang, R**., & Zhang, Y., et al. (2014). Safety, tolerability, and pharmacokinetics (PK) of rilotumumab combined with cisplatin and capecitabine in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. *Journal of Clinical Oncology 32:15_suppl, 4051-4051.* DOI:10.1200/jco.2014.32.15_suppl.4051
37. Hale, M. D., Oliner, K. S., **Tang, R**., Vallone, J. G., Klement, I., Webster, S., Chen, L., Loh, E., & Patterson, S. D. (2014). Evaluation of Met Staining in Gastric/Gastroesophageal Junction (G/Gej) Tumor Samples As a Biomarker for Rilotumumab (R) Benefit. *Annals of Oncology, 25, iv74. Elsevier.* doi.org/10.1093/annonc/mdu326.55.
38. Loberg, R. D., **Tang, R.,** & Oliner, K. S. (2014). Prevalence of MET and HER2 biomarkers in stage IV gastric cancer. *Journal of Clinical Oncology 32:15_suppl, 4048-4048.* DOI:10.1200/jco.2014.32.15_suppl.4048.
39. McCaffery, I., Tudor, Y., Deng, H., **Tang, R.,** Suzuki, S., Badola, S., Kindler, H. L., Fuchs, C. S., Loh, E., & Patterson, S. D., et al. (2013). Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor. *Clinical Cancer Research, 19(15), 4282-4289.* doi: 10.1158/1078-0432.CCR-12-1840.
40. Oliner, K., **Tang, R.,** Anderson, A., Lan, Y., Iveson, T., Donehower, R., Jiang, Y., Dubey, S., & Loh, E. (2012). O-0011 Evaluation of Met-Pathway Biomarkers in a Phase 2 Study of Rilotumumab Plus Epirubicin, Cisplatin, and Capecitabine in Gastric/Esophagogastric Junction

Cancer. *Annals of Oncology, 23, iv8. Elsevier.* DOI: https://doi.org/10.1016/S0923-7534(19)66475-6.

41. Doshi, S., Kathman, S., **Tang, R.,** Gisleskog, P. O., Loh, E., Dubey, S., Jiang, Y., Oliner, K. S., Donehower, R. C., & Iveson, T., et al. (2012). Modeling the combined efficacy of rilotumumab (R; AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) for the treatment of locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. *Journal of Clinical Oncology 30:15_suppl, 2594-2594.* DOI:10.1200/jco.2012.30.15_suppl.2594.

42. Oliner, K. S., **Tang, R.,** Anderson, A., Lan, Y., Iveson, T., Donehower, R. C., Jiang, Y., Dubey, S., & Loh, E. (2012). Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. *Journal of Clinical Oncology 30:15_suppl, 4005-4005.* DOI:10.1200/jco.2012.30.15_suppl.4005.

43. Zhu, M., **Tang, R.,** Doshi, S., Oliner, K. S., Kathman, S., Gisleskog, P. O., Dubey, S., Jiang, Y., Donehower, R. C., & Iveson, T., et al. (2012). Exposure-response (ER) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or esophagogastric junction (G/EGJ) cancer. *Journal of Clinical Oncology 30:15_suppl, 2535-2535.* DOI:10.1200/jco.2012.30.15_suppl.2535

44. Lu, J., Deng, H., **Tang, R.,** Hsu, C., Kindler, H. L., Fuchs, C., Gansert, J., Bray, S., Loh, E., & Zhu, M. (2011). Exposure-response (ER) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic cancer (mPC). *Journal of Clinical Oncology 2011 29:15_suppl, 4049-4049*. DOI:10.1200/jco.2011.29.15_suppl.4049.

45. McCaffery, I., Tudor, Y., Deng, H., **Tang, R**., Badola, S., Kindler, H. L., Fuchs, C. S., Loh, E., Patterson, S. D., & Chen, L., et al. (2011). Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) in combination with gemcitabine (G). *Journal of Clinical Oncology, 29(15_suppl), 4041-4041.* DOI:10.1200/jco.2011.29.15_suppl.4041

46. **Tang, R**., & Feng, T. (2009). A variable-sized sliding-window approach for genetic association studies via principal component analysis. *Annals of Human Genetics, 73(6), 631-637. Wiley Online Library*. doi: 10.1111/j.1469-1809.2009.00543.

47. Sha, Q., **Tang, R.,** & Zhang, S. (2009). Detecting susceptibility genes for rheumatoid arthritis based on a novel sliding-window approach. *BMC Proceedings, 3, 1-5. BioMed Central.* doi.org/10.1186/1753-6561-3-S7-S14

48. Fridley, B. L., McDonnell, S. K., Rabe, K. G., **Tang, R.,** Biernacka, J. M., Sinnwell, J. P., Rider, D. N., & Goode, E. L. (2009). Single versus multiple imputation for genotypic data. *BMC Proceedings, 3, 1-4. BioMed Central.* doi: 10.1186/1753-6561-3-s7-s7.

49. Biernacka, J. M., **Tang, R.,** Li, J., MvDonnel, S. K., Rabe, K. G., Sinnwell, J. P., & Rider, D. N. (2009). Mariza de Andrade, Ellen L Goode, and Brooke L Fridley. Assessment of genotype

imputation methods. *BMC Proceedings, Genetic Analysis Workshop, 16, 1-5.* doi: 10.1186/1753-6561-3-s7-s5.

50. **Tang, R.,** Sinnwell, J. P., Li, J., Rider, D. N., de Andrade, M., & Biernacka, J. M. (2009). Identification of genes and haplotypes that predict rheumatoid arthritis using random forests. *BMC Proceedings, 3(7), 1-5. BioMed Central.* doi: 10.1186/1753-6561-3-s7-s68.
51. Li, J., **Tang, R.,** Biernacka, J. M., & De Andrade, M. (2009). Identification of gene-gene interaction using principal components. *BMC Proceedings, 3(7), 1-6. BioMed Central.* doi.org/10.1186/1753-6561-3-S7-S78
52. Biernacka, J. M., **Tang, R.,** Li, J., McDonnell, S. K., Rabe, K. G., Sinnwell, J. P., Rider, D. N., & De Andrade, M. (2009). Assessment of genotype imputation methods. *BMC Proceedings, 3(7), 1-5. BioMed Central.* doi: 10.1186/1753-6561-3-s7-s5.
53. **Tang, R.,** Wang, F., Sha, Q., Zhang, S., & Chen, H.-S. (2007). Genome-wide association tests by using block information in family data. *BMC Proceedings, 1(1), 1-5. BioMed Central.* doi: 10.1186/1753-6561-1-s1-s149.

ICSA Activities*

Dr. Rui (Sammi) Tang has significantly impacted the statistical field through her roles across several key organizations. At the International Chinese Statistical Association (ICSA) from 2019-2021, she served as an organizing committee member, session organizer, invited speaker, and fundraising chair, showcasing her commitment to data analytics advancement. She has supported ICSA sponsorship again this year through her company .

Professional Committees*

- DIA (Drug Information Association)
    - Team Lead: small population rare disease work stream 2015- 2023
    - Adaptive Design Scientific Working Group Leadership team 2017-2023
- DIA Complex Innovative Design Statistical symposium Organizing committee 2019-2022
- Boston Club for C-level women leadership, Corporate Connection Committee 2023-current
- Co-founder and Vice Present of DahShu, a non-profit organization to promote Data Sciences 2015-current http://dahshu.org/ ; Created monthly KOL seminar organizer to the statistical and data science community;
- The Bay area Biotech-Pharma statistics (BBSW) https://www.bbsw.org/ advisory board members 2018-2021 ; Supported Series of events with local ASA-SF chapter collaboration with BBSW
- New England Statistical Society (NESS) https://nestat.org/ Society Council 2018-2022
- Oncology estimand working group- A cross-industry international working group (Treatment switch, Solid Tumor teams)https://oncoestimand.github.io/home/oncoestimand.html
- ASA/DIA Master Protocol Working Group leadership committee 2021-2023
- ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2021 Steering committee
- ASA JSM 2022 Program Committee Associate Chair 2021-2022

- ASA Boston Chapter Pharmaceutical Symposium Organizing Committee 2020-2022
- New England Rare Disease Statistics (NERDS) yearly Conference 2019-current Served as Co-founder, Chair and steering committee members
- International Chinese Statistical Association (ICSA) Symposium Organizing committee 2019-2020
- SCT (Society of Clinical Trials) Program committee and membership committee 2014-2018
- BayHelix Boston Chapter Head, a nonprofit professional global organization of life science business leaders 2020- current
- APBC (Asian Pacific Bioinformatics Conference) program committee&local organizer 2016

Honors and Awards*

 Recognized as a **Leader in Innovation** for driving AI/ML applications in clinical trial design and medical writing
 Internal award(s) for **Transformational Leadership** and **Global Collaboration**
 Recipient of **Excellence in Drug Development** or **Outstanding Scientific Contribution** awards within Company
 Recognition from **cross-functional leadership** for establishing advance analytics and modernizing statistical and evidence generation practices

Statements*

I am honored to be considered for the role of President of ICSA—a community I have proudly served as an organizing committee member, session organizer, invited speaker, and fundraising chair from 2019 to 2021. ICSA has long been a home for collaboration, excellence, and advancement in statistical science, and I am passionate about building on this strong foundation to lead our association into its next chapter.
With over two decades of experience across both industry and academia, I bring a unique perspective that bridges scientific innovation with real-world impact. I currently serve as an adjunct professor in the Yale Biostatistics Department and lead global quantitative sciences, evidence generation, and medical writing in drug development. Throughout my career, I have championed advanced analytics, real-world data, and AI/ML integration to accelerate drug development and deliver therapies to patients. I believe this kind of boundary-crossing mindset is essential for the future of our profession.
As President, I will focus on:

- **Bridging academia and industry** by creating platforms for cross-sector collaboration, mentorship, and leadership development.
- **Promoting impactful real-world collaborations** that highlight the value of statistical science in improving health, policy, and innovation.
- **Fostering an inclusive and globally connected ICSA community**, amplifying diverse voices across disciplines, geographies, and career stages.
- **Expanding strategic partnerships** with organizations such as ASA, ENAR, DIA, and international societies to elevate the visibility of our members, foster joint initiatives, and promote greater influence for ICSA in global forums.
- **Supporting emerging areas of statistics**, including AI, data science, regulatory science, and evidence generation, to keep ICSA at the forefront of innovation.

I believe in the collective strength of our community. With your support, ICSA can become not only a hub of scientific excellence, but also a globally respected voice that connects, empowers, and leads.

Let’s shape the future of statistics—together.